A carregar...
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
Although androgen ablation therapy is the foundation of current prostate cancer treatment, most patients ultimately develop castration-resistant disease. One proposed mechanism to account for androgen receptor (AR) activity in the castrate environment is via crosstalk with other signaling pathways....
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3582879/ https://ncbi.nlm.nih.gov/pubmed/22614157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2012.1487 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|